Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Syncona Chief Executive Officer Chris Hollowood says: "We are pleased to see the Beacon team continue to make significant progress as they progress towards key milestones, including the upcoming initiation of a pivotal trial. We also look forward to seeing further longer-term efficacy read-outs from Skyline in 2024, which will be key to demonstrating the durability profile of AGTC-501."

Current stock price: 126.83 pence, untraded

12-month change: down 29%

By Sabrina Penty, Alliance News reporter

Comments and questions to

Copyright 2023 Alliance News Ltd. All Rights Reserved.